|
1
|
Fearon KC, Barber MD, Falconer JS,
McMillan DC, Ross JA and Preston T: Pancreatic cancer as a model:
Inflammatory mediators, acute-phase response, and cancer cachexia.
World J Surg. 23:584–588. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McMillan DC, Scott HR, Watson WS, Preston
T, Milroy R and McArdle CS: Longitudinal study of body cell mass
depletion and the inflammatory response in cancer patients. Nutr
Cancer. 31:101–105. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McMillan DC, Watson WS, O'Gorman P,
Preston T, Scott HR and McArdle CS: Albumin concentrations are
primarily determined by the body cell mass and the systemic
inflammatory response in cancer patients with weight loss. Nutr
Cancer. 39:210–213. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meek CL, Wallace AM, Forrest LM and
McMillan DC: The relationship between the insulin-like growth
factor-1 axis, weight loss, an inflammation-based score and
survival in patients with inoperable non-small cell lung cancer.
Clin Nutr. 29:206–209. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McMillan DC: An inflammation-based
prognostic score and its role in the nutrition-based management of
patients with cancer. Proc Nutr Soc. 67:pp. 257–262. 2008;
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McMillan DC: Systemic inflammation,
nutritional status and survival in patients with cancer. Curr Opin
Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dowell JE: Small cell lung cancer: Are we
making progress? Am J Med Sci. 339:68–76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou T, Hong S, Hu Z, Hou X, Huang Y, Zhao
H, Liang W, Zhao Y, Fang W, Wu X, et al: A systemic
inflammation-based prognostic scores (mGPS) predicts overall
survival of patients with small-cell lung cancer. Tumour Biol.
36:337–343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Forrest LM, McMillan DC, McArdle CS,
Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic
scores based on the systemic inflammatory response in patients with
inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Crumley AB, Stuart RC, McKernan M, Going
JJ, Shearer CJ and McMillan DC: Comparison of pre-treatment
clinical prognostic factors in patients with gastro-oesophageal
cancer and proposal of a new staging system. J Gastrointest Surg.
14:781–787. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roxburgh CS, Platt JJ, Leitch EF, Kinsella
J, Horgan PG and McMillan DC: Relationship between preoperative
comorbidity, systemic inflammatory response, and survival in
patients undergoing curative resection for colorectal cancer. Ann
Surg Oncol. 18:997–1005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan H, Shao ZY, Xiao YY, Xie ZH, Chen W,
Xie H, Qin GY and Zhao NQ: Comparison of the glasgow prognostic
score (GPS) and the modified glasgow prognostic score (mGPS) in
evaluating the prognosis of patients with operable and inoperable
non-small cell lung cancer. J Cancer Res Clin Oncol. 142:1285–1297.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu L, Chen S, Ma S and Zhang S: Glasgow
prognostic score predicts prognosis of non-small cell lung cancer:
A meta-analysis. Springerplus. 5:4392016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Temel JS, Abernethy AP, Currow DC, Friend
J, Duus EM, Yan Y and Fearon KC: Anamorelin in patients with
non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2):
Results from two randomised, double-blind, phase 3 trials. Lancet
Oncol. 17:519–531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Takayama K, Katakami N, Yokoyama T, Atagi
S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, et
al: Anamorelin (ONO-7643) in Japanese patients with non-small cell
lung cancer and cachexia: Results of a randomized phase 2 trial.
Support Care Cancer. 24:3495–3505. 2016. View Article : Google Scholar : PubMed/NCBI
|
